Revenue: As of FY2025 Q3, the actual value is USD 11.45 M.EPS: As of FY2025 Q3, the actual value is USD -0.74.EBIT: As of FY2025 Q3, the actual value is USD -16.45 M.<h3>Health Solutions Segment</h3><ul><li>Net Sales: $38.4 million for the nine months ended June 30, 2025.</li><li>Cost of Goods Sold: $28.1 million for the nine months ended June 30, 2025.</li><li>Gross Profit: $10.3 million for the nine months ended June 30, 2025.</li><li>Segment Expenses: $33.8 million for the nine months ended June 30, 2025, including salaries and wages ($14.4 million), depreciation and amortization ($2.6 million), and share-based compensation ($2.4 million).</li><li>Operating Loss: -$23.6 million for the nine months ended June 30, 2025.</li></ul><h3>Consumer Products Segment</h3><ul><li>Net Sales: $2.7 million for the nine months ended June 30, 2025.</li><li>Cost of Goods Sold: $2.6 million for the nine months ended June 30, 2025.</li><li>Gross Profit: $31,000 for the nine months ended June 30, 2025.</li><li>Segment Expenses: $8.6 million for the nine months ended June 30, 2025, including share-based compensation ($2.0 million).</li><li>Operating Loss: -$8.6 million for the nine months ended June 30, 2025.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: -$15.7 million for the nine months ended June 30, 2025.</li><li>Investing Cash Flow: $13.3 million for the nine months ended June 30, 2025, primarily from proceeds from the sale of assets.</li><li>Financing Cash Flow: $3.2 million for the nine months ended June 30, 2025, mainly from private placements.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: SRx Health Solutions Inc. aims to expand its leadership role in Canada’s specialty healthcare landscape by leveraging its established footprint and growing pipeline of partnerships. The company plans to address liquidity constraints and operational challenges through restructuring under the Companies’ Creditors Arrangement Act (CCAA) in Canada.</li><li>Non-Core Business: The company is evaluating strategic alternatives for its U.S. pet food business, including potential restructuring, divestiture, or wind-down, due to significant liquidity constraints and operating losses.</li></ul>

SRX Health Solutions | 10-Q: FY2025 Q3 Revenue: USD 11.45 M